All articles tagged with #bone remodeling
A study reveals a vitamin K–dependent signaling pathway in osteoblasts that regulates osteoclast maturation and bone resorption via GAS6-TAM signaling; deleting γ-glutamyl carboxylase in osteoblasts increases bone mass by reducing resorption, while GAS6 stimulates osteoclast formation; elevated GAS6 lowers bone density in vivo, highlighting GAS6/TAM signaling as a potential osteoporosis target.
Animal studies show a single injection can restore arthritic joints to a healthy state within 4–8 weeks, rebuilding cartilage and bone and signaling repair pathways; researchers are also pursuing a patch approach for larger defects, with safety-focused human trials expected by late 2027 under the NITRO program, though a clinic-ready treatment is not yet available.
Scientists identified GPR133 as a receptor that senses mechanical strain and coordinates osteoblasts and osteoclasts, acting as a switch to boost bone formation while reducing bone degradation. In mice, activating GPR133 with the compound AP503 increased bone strength in both healthy and osteoporosis models, suggesting a balanced, potentially safer new approach to osteoporosis treatment, though human trials are needed.